Aptevo Therapeutics (APVO) Stock: Buy, Sell, or Hold?
APVO - Aptevo Therapeutics Inc
$1.76
0.00 (0.00%)
â˛
5d:
-6.88%
30d:
-32.31%
90d:
-60.63%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When APVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: APVO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: APVO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: APVO is currently trading at $1.76, which is considered slightly low relative to its 30-day fair value range of $1.69 to $2.25.
Technical Outlook: Technically, APVO is in a strong downtrend. The price is currently testing key support at $1.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: APVO scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.50 (+1348.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, APVO is in a strong downtrend. The price is currently testing key support at $1.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: APVO scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.50 (+1348.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.69 -
$2.25
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1348.9% below Wall St target ($25.50)
- WARNING: Composite score 34/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.69 -
$2.25
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.75
Resistance Level
$1.98
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.17
Wall Street Target
$25.50
(+1348.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 03, 2026 6:32 PM ET
Data refreshes hourly during market hours. Next update: 7:32 PM
Data refreshes hourly during market hours. Next update: 7:32 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is APVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
